Table 5.

Patients with disease progression

	Age (yr)	Clinical presentation/Initial diagnosis	Treatment	Disease progression/recurrence Treatment	Follow-up (since index CNB)
1	73	No personal or family hx of BC Screening Mx: Ca++ (0.5 cm) CNB: apo FLCIS with necrosis (ER+) EXC: PLCIS, margins negative	Excision No XRT No HT	24 mo from initial diagnosis MRI: linear NME (3.3 cm) Pathology: FLCIS with microinvasion; margins negative; 0/2 SLNs Excision with SLN	87 mo NED
2	75	History of contralateral DCIS and ipsilateral PLCIS (s/p excision with negative margins) Family history of BC Screening Mx: Ca++ (0.3 cm) CNB: apo PLCIS with necrosis (ER+/HER2−) EXC: apo PLCIS with microinvasion; margins negative	Excision No XRT No HT	15 mo from initial diagnosis Mx: Ca++ Pathology: PLCIS with microinvasion; margin positive for microinvasion Excision, no SLN; patient declined mastectomy/re-excision 29 mo after index CNB mass at the site of prior excision Pathology: Invasive carcinoma with mixed features (2.6 cm), DCIS, PLCIS; margins negative; 0/5 SLN Excision with SLN; XRT; CMF	73 mo DOD
3	57	History of ipsilateral tubular carcinoma s/p excision with negative SLN, XRT, and tamoxifen switched to anastrozole, then raloxifene Screening Mx: Ca++ (2.4 cm) CNB: apo FLCIS with necrosis (ER+/HER2−) EXC: apo FLCIS; margins negative	Excision No XRT Raloxifene (for prior tubular carcinoma)	59 mo after index CNB Palpable lesion US: irregular mass (1.2 cm) Pathology: P-ILC (0.15 and 0.1 cm), PLCIS, FLCIS; margins negative Mastectomy, continue raloxifene	65 mo NED

BC: breast cancer; Mx: mammogram; Ca++: calcifications; CNB: core needle biopsy; apo: apocrine; FLCIS: florid lobular carcinoma in situ; EXC: excision; PLCIS: pleomorphic lobular carcinoma in situ; XRT: radiation therapy; HT: hormonal therapy; NME: non-mass enhancement; SLN: sentinel lymph node; NED: no evidence of disease; DOD: died of disease; CMF: cyclophosphamide, methotrexate, fluorouracil; P-ILC: pleomorphic invasive lobular carcinoma